R744 + R744

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemodialysis Patients

Conditions

Hemodialysis Patients

Trial Timeline

Jan 1, 2007 → Oct 1, 2008

NCT ID

NCT00433888

About R744 + R744

R744 + R744 is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemodialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00433888. Target conditions include Hemodialysis Patients.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis Patients were approved

Approved (2) Terminated (0) Active (13)

🔄R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3

🔄R744Chugai PharmaceuticalPhase 3

🔄roxadustatAstellas PharmaPhase 3

🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3

🔄roxadustatAstellas PharmaPhase 3

✅DoravirineMerckApproved

🔄PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00433849	Phase 3	Completed	Feb 1, 2007	Nov 1, 2008	Peritoneal Dialysis Patients
NCT00433615	Phase 3	Completed	Feb 1, 2007	Nov 1, 2008	Anemia in Pre-Dialysis Patients
NCT00433888	Phase 3	Completed	Jan 1, 2007	Oct 1, 2008	Hemodialysis Patients

Competing Products

20 competing products in Hemodialysis Patients

See all competitors

Product	Company	Stage	Hype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Chugai Pharmaceutical	Phase 3	40
R744	Chugai Pharmaceutical	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
ASP1585	Astellas Pharma	Phase 2	35
Kiklin capsules	Astellas Pharma	Pre-clinical	26
Doravirine	Merck	Approved	43
BPS804 + Placebo	Novartis	Phase 2	27
PA21 + Sevelamer hydrochloride	Kissei Pharmaceutical	Phase 3	40
PA21 + PA21 + PA21 + PA21 + Placebo	Kissei Pharmaceutical	Phase 2	35
PA21	Kissei Pharmaceutical	Phase 3	40
PA21	Kissei Pharmaceutical	Phase 3	40
[¹⁴C]Etelcalcetide	Amgen	Phase 1	29
Epoetin Hospira	Pfizer	Phase 3	40
Epoetin Hospira	Pfizer	Phase 3	40
sodium thiosulfate	Sanofi	Pre-clinical	26
Enoxaparine	Sanofi	Approved	43
Alirocumab 150 MG/ML [Praluent]	Regeneron Pharmaceuticals	Phase 3	36